US2009054458A1PendingUtilityA1
Use of a polymorph of flibanserin for treating disease
Est. expiryAug 2, 2021(expired)· nominal 20-yr term from priority
A61P 25/20A61P 25/22A61P 25/18A61P 25/28A61P 25/00A61P 25/16A61K 31/496C07D 235/26C07D 403/06C07D 233/26A61P 15/00
60
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The invention relates to the polymorph A of flibanserin, to a technical process for the preparation thereof, as well as to the use thereof for preparing medicaments.
Claims
exact text as granted — not AI-modified1 ) A method for treating a disease that is treatable with a compound having an affinity for the 5-HT 1A or 5-HT 2 -receptors in a patient, comprising administering to said patient a therapeutically effective amount of a crystalline polymorph, designated form A, of flibanserin 1,
having an endothermic maximum at about 161° C. which occurs during thermal analysis using DSC.
2 ) A method for treating a disease that is treatable with a compound having an affinity for the 5-HTIA or 5-HT2-receptors in a patient, comprising administering to said patient a therapeutically effective amount of flibanserin 1 comprising form A according to claim 1 .
3 ) A method for treating a disease that is treatable with a compound having an affinity for the 5-HT,A or 5-HT 2 -receptors in a patient, comprising administering to said patient a therapeutically effective amount of a polymorph of flibanserin 1 characterized by the following X-ray powder diffraction pattern:
Peak
Rel.
Angle
d-value
d-value
width
Peak int
Back. int
int
[°2θ]
α1 [Å]
α2 [Å]
[°2θ]
[counts]
[counts]
[%]
Signif.
5.195
16.9967
17.0390
0.960
8
69
0.1
1.05
9.045
9.7689
9.7931
0.100
92
96
1.3
0.97
9.335
9.4660
9.4896
0.080
114
98
1.6
0.88
10.025
8.8160
8.8379
0.140
400
100
5.5
7.18
10.595
8.3430
8.3637
0.140
204
102
2.8
3.46
11.290
7.8309
7.8503
0.140
467
104
6.4
6.91
13.225
6.6891
6.7058
0.180
548
112
7.5
13.10
14.595
6.0642
6.0793
0.180
404
121
5.5
9.17
15.460
5.7268
5.7410
0.140
4186
125
57.3
23.20
16.655
5.3185
5.3317
0.200
515
130
7.0
12.38
17.085
5.1856
5.1985
0.100
1347
132
18.4
2.78
17.285
5.1260
5.1388
0.060
1399
135
19.1
2.26
17.420
5.0866
5.0992
0.100
1204
135
16.5
4.71
18.140
4.8863
4.8984
0.180
1043
139
14.3
13.14
18.650
4.7538
4.7656
0.120
1063
142
14.5
0.91
19.140
4.6332
4.6447
0.140
7310
144
100.0
32.77
19.820
4.4757
4.4869
0.160
3624
146
49.6
9.02
20.080
4.4184
4.4294
0.140
5402
149
73.9
21.06
20.385
4.3530
4.3638
0.160
2652
149
36.3
23.25
21.215
4.1845
4.1949
0.160
369
154
5.0
5.78
21.890
4.0570
4.0670
0.200
773
156
10.6
3.09
22.630
3.9259
3.9357
0.280
4277
161
58.5
74.66
23.210
3.8291
3.8386
0.120
484
164
6.6
3.33
24.355
3.6516
3.6607
0.060
2725
169
37.3
1.16
24.610
3.6144
3.6234
0.140
3540
172
48.4
17.08
24.995
3.5596
3.5684
0.100
529
174
7.2
1.01
25.260
3.5228
3.5316
0.120
557
174
7.6
3.02
26.575
3.3514
3.3597
0.240
2421
182
33.1
42.58
27.155
3.2811
3.2893
0.140
676
185
9.2
1.32
27.310
3.2629
3.2710
0.100
767
185
10.5
2.75
27.865
3.1991
3.2071
0.120
420
188
5.7
1.08
28.210
3.1608
3.1686
0.100
1467
190
20.1
0.79
28.325
3.1482
3.1560
0.140
1789
190
24.5
4.41
28.650
3.1132
3.1210
0.180
1204
190
16.5
11.65
29.520
3.0234
3.0309
0.220
1011
196
13.8
15.74
30.250
2.9521
2.9594
0.120
159
199
2.2
1.22
31.105
2.8729
2.8800
0.360
282
204
3.9
8.14
31.905
2.8026
2.8096
0.100
339
207
4.6
0.96
32.350
2.7651
2.7720
0.120
237
210
3.2
3.01
33.300
2.6884
2.6950
0.180
1347
216
18.4
14.06
33.640
2.6620
2.6686
0.100
404
216
5.5
1.45
34.880
2.5701
2.5765
0.200
202
222
2.8
1.04
35.275
2.5422
2.5486
0.240
299
225
4.1
4.84
36.055
2.4890
2.4952
0.280
202
228
2.8
3.78
36.910
2.4333
2.4393
0.320
169
234
2.3
0.90
37.160
2.4175
2.4235
0.120
216
234
3.0
2.14
37.680
2.3853
2.3912
0.240
240
237
3.3
1.58
39.435
2.2831
2.2888
0.280
449
246
6.1
2.67
39.675
2.2698
2.2755
0.080
396
246
5.4
0.82
40.325
2.2347
2.2403
0.160
520
250
7.1
0.95
40.930
2.2031
2.2086
0.120
480
253
6.6
2.66
41.445
2.1769
2.1823
0.240
372
256
5.1
2.65
41.990
2.1499
2.1552
0.120
538
259
7.4
1.31
42.670
2.1172
2.1225
0.160
428
262
5.9
1.45
43.145
2.0950
2.1002
0.120
433
266
5.9
1.50
44.190
2.0478
2.0529
0.160
376
269
5.1
0.89
46.095
1.9675
1.9724
0.160
279
279
3.8
0.86
46.510
1.9509
1.9558
0.240
310
282
4.2
0.87
48.305
1.8826
1.8872
0.200
506
292
6.9
2.06
48.900
1.8610
1.8657
0.240
615
296
8.4
1.67
50.330
1.8115
1.8160
0.160
437
303
6.0
1.73
51.035
1.7881
1.7925
0.080
416
306
5.7
0.93
53.550
1.7099
1.7141
0.480
177
317
2.4
2.84
54.500
1.6823
1.6865
0.400
130
324
1.8
1.37
55.420
1.6565
1.6606
0.320
130
328
1.8
1.72
56.220
1.6348
1.6389
0.320
121
331
1.7
0.87
56.770
1.6203
1.6243
0.240
142
335
1.9
1.59
57.405
1.6039
1.6079
0.240
112
339
1.5
1.19
58.500
1.5764
1.5804
0.240
67
342
0.9
1.57
4 ) A method for treating a disease that is treatable with a compound having an affinity for the 5-HT 1A or 5-HT 2 -receptors in a patient, comprising administering to said patient a therapeutically effective amount of a polymorph of flibanserin 1 characterized by having an X-ray powder diffraction pattern as shown in FIG. 1 .
5 ) A method for treating a disease selected from depression, schizophrenia, Parkinson's, anxiety, sleep disturbances, sexual and mental disorders and age associated memory impairment in a patient, comprising administering to said patient a therapeutically effective amount of form A according to claim 1 .
6 ) A method for treating a disease selected from depression, schizophrenia, Parkinson's, anxiety, sleep disturbances, sexual and mental disorders and age associated memory impairment in a patient, comprising administering to said patient a therapeutically effective amount of flibanserin 1 comprising form A according to claim 1 .
7 ) A method for treating a disease selected from depression, schizophrenia, Parkinson's, anxiety, sleep disturbances, sexual and mental disorders and age associated memory impairment in a patient, comprising administering to said patient a therapeutically effective amount of a polymorph of flibanserin 1 characterized by the X-ray powder diffraction pattern according to claim 3 .
8 ) A method for treating a disease selected from depression, schizophrenia, Parkinson's, anxiety, sleep disturbances, sexual and mental disorders and age associated memory impairment in a patient, comprising administering to said patient a therapeutically effective amount of a polymorph of flibanserin 1 characterized by having an X-ray powder diffraction pattern as shown in FIG. 1 .Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.